title: Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases.
abstract: From February 1996 to December 1998, 95 patients affected with colorectal liver metastases underwent the positioning of an intraarterial hepatic catheter by a transcutaneous subclavian access, under local anesthesia. All patients were evaluated for catheter implantation complications. Moreover, 61 patients of 95 treated at our center were retrospectively evaluated for results of chemotherapy performed with two different schedules of hepatic artery infusion (HAI) combined with systemic chemotherapy (SC). Eleven patients (group A) were treated with combined SC (5-fluorouracil continuous infusion) and HAI (floxuridine). A subsequent 50 patients underwent HAI (floxuridine, 4 cycles) followed, if a response or stable disease were observed, by combined SC and HAI (group B). Three cases of aneurysm of subclavian artery occurred, which were treated by the positioning of a radiologic arterial stent and the reimplantation of the catheter by a femoral access. Thrombosis of the hepatic artery was registered in four cases. We observed 10.5% occurrence of dislocation of the catheter, which was always moved again in the hepatic artery. In group A, with 45% clinical objective response rate and 10% stable disease rate, median survival time and median time to extrahepatic progression were 9 and 6 months, respectively. In group B, we observed 44% clinical objective responses and 26% stable disease after HAI. Patients without disease progression and therefore submitted to sequential SC and HAI had a median survival time of 21 months and a median time to extrahepatic progression of 16 months. The development of the mini-invasive technique of implantation of an arterial port can avoid laparotomy for HAI. Percutaneous implantation of an arterial port has a low rate of technical complications. HAI followed by combined systemic and regional chemotherapy has good results in terms of survival and time to extrahepatic progression.
authors.affiliation: Service of Surgical Oncology, University of Turin, Molinette Hospital, Torino, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Zanon
authors.forename: M
authors.initials: M
authors.lastname: Grosso
authors.forename: R
authors.initials: R
authors.lastname: Clara
authors.forename: O
authors.initials: O
authors.lastname: Alabiso
authors.forename: I
authors.initials: I
authors.lastname: Chiappino
authors.forename: S
authors.initials: S
authors.lastname: Miraglia
authors.forename: R
authors.initials: R
authors.lastname: Martinotti
authors.forename: M
authors.initials: M
authors.lastname: Bortolini
authors.forename: M
authors.initials: M
authors.lastname: Rizzo
authors.forename: C
authors.initials: C
authors.lastname: Gazzera
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000473:pathology; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects / Q000379:methods*; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013348:Subclavian Artery; D016019:Survival Analysis